Active substance
Verapamil
- SFDA 7
- US FDA 78
- Health Canada 5
- US price lines 13
- NHS prices 8
- WHO EML 3
- Safety 8
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ISOPTIN AMP 2.5MG-ML | 2.5 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 14.20 | NCE · Prescription | Abbott Laboratories | Valid |
| ISOPTIN RETARD TAB 120MG | 120 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 20.15 | NCE · Prescription | Abbott Laboratories | Valid |
| ISOPTIN S.R 240MG F.COATED TAB | 240 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 41.95 | Generic · Prescription | Abbott Laboratories | Valid |
| ISOPTIN TABLETS 40 MG. | 40 mg | Tablet · Oral use | 50 Blister | SAR 18.10 | NCE · Prescription | Abbott Laboratories | Valid |
| ISOPTIN TABLETS 80 MG. | 80 mg | Tablet · Oral use | 20 Blister | SAR 14.70 | NCE · Prescription | Abbott Laboratories | Valid |
| ISOVERA | 2.5 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 14.20 | Generic · Prescription | Saudi Amarox | Valid |
| Verapamil QO | 2.5 mg | Solution for injection · Intravenous use | 5 Vial | SAR 14.20 | Generic · Prescription | Qomel Co | Valid |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ CARDIAC ARREST, CARDIOVASCULAR EMERGENCIES AND/OR DYSRHYTHMIAS; ARRHYTHMIA; ATRIAL FIBRILLATION; BURN MANAGEMENT; CARDIOMYOPATHY; HYPERTENSION; SUPRAVENTRICULAR TACHYCARDIA; VENTRICULAR TACHYCARDIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML) | solution · intravenous | EXELA PHARMA | Prescription | 30 Mar 1984 |
| VERAPAMIL HYDROCHLORIDE | 120MG | tablet · oral | WATSON LABS | Prescription | 1 Oct 1986 |
| VERAPAMIL HYDROCHLORIDE | 80MG | tablet · oral | WATSON LABS | Prescription | 1 Oct 1986 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML); 10MG/4ML (2.5MG/ML) | solution · intravenous | HOSPIRA | Prescription | 6 May 1987 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML) | solution · intravenous | HOSPIRA | Prescription | 6 May 1987 |
| VERAPAMIL HYDROCHLORIDE | 120MG; 40MG; 80MG | tablet · oral | HERITAGE | Prescription | 5 Apr 1988 |
| VERELAN | 120MG; 240MG; 180MG; 360MG | capsule, extended release · oral | AZURITY | Prescription | 29 May 1990 |
| VERAPAMIL HYDROCHLORIDE | 40MG | tablet · oral | WATSON LABS | Prescription | 29 Jun 1993 |
| VERELAN PM | 100MG; 200MG; 300MG | capsule, extended release · oral | AZURITY | Prescription | 25 Nov 1998 |
| VERAPAMIL HYDROCHLORIDE | 120MG; 180MG; 240MG | capsule, extended release · oral | MYLAN | Prescription | 20 Apr 1999 |
| VERAPAMIL HYDROCHLORIDE | 120MG; 240MG | tablet, extended release · oral | STRIDES PHARMA INTL | Prescription | 25 May 1999 |
| VERAPAMIL HYDROCHLORIDE | 240MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 17 Sep 2009 |
| VERAPAMIL HYDROCHLORIDE | 120MG; 180MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 3 Aug 2011 |
| VERAPAMIL HYDROCHLORIDE | 180MG; 240MG; 120MG | tablet, extended release · oral | CADILA PHARMS LTD | Prescription | 5 May 2017 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML); 10MG/4ML (2.5MG/ML) | solution · intravenous | SOMERSET THERAPS LLC | Prescription | 18 Jun 2018 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML); 10MG/4ML (2.5MG/ML) | solution · intravenous | SOMERSET | Prescription | 18 Jun 2018 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML); 10MG/4ML (2.5MG/ML) | solution · intravenous | MICRO LABS | Prescription | 28 Dec 2018 |
| VERAPAMIL HYDROCHLORIDE | 10MG/4ML (2.5MG/ML); 5MG/2ML (2.5MG/ML) | solution · intravenous | NEPHRON | Prescription | 17 Mar 2020 |
| VERAPAMIL HYDROCHLORIDE | 5MG/2ML (2.5MG/ML); 10MG/4ML (2.5MG/ML) | solution · intravenous | CAPLIN | Prescription | 25 Mar 2020 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 6 Jul 2020 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | ZYDUS PHARMS | Prescription | 15 Oct 2020 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | GLAND | Prescription | 15 Oct 2020 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | HERITAGE | Prescription | 17 Mar 2022 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | MANKIND PHARMA | Prescription | 15 Jun 2022 |
| VERAPAMIL HYDROCHLORIDE | 2.5MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 23 Apr 2024 |
53 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-VERAP | 00782483 | 80 MG | TABLET · ORAL | AA PHARMA INC |
| AA-VERAP | 00782491 | 120 MG | TABLET · ORAL | AA PHARMA INC |
| ISOPTIN SR | 01907123 | 120 MG | TABLET (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| MYLAN-VERAPAMIL SR | 02210347 | 120 MG | TABLET (EXTENDED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| VERAPAMIL HYDROCHLORIDE INJECTION USP | 02166739 | 2.5 MG / ML | LIQUID · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | VERAPAMIL 120 MG TABLET | $0.08873 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL 40 MG TABLET | $0.11259 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL 80 MG TABLET | $0.07325 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 120 MG CAPSULE | $2.74927 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 120 MG TABLET | $0.17779 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 180 MG CAPSULE | $2.08661 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 180 MG TABLET | $0.19107 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 240 MG CAPSULE | $3.1476 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL ER 240 MG TABLET | $0.17613 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL SR 120 MG CAPSULE | $2.74927 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL SR 180 MG CAPSULE | $2.08661 | per EA | 23 Sep 2026 |
| US NADAC | VERAPAMIL SR 240 MG CAPSULE | $3.1476 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Verapamil 120mg modified-release tablets | £9.50 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 120mg tablets | £4.14 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 160mg tablets | £31.53 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 240mg modified-release tablets | £5.55 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 40mg tablets | £1.86 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 40mg/5ml oral solution sugar free | £158.85 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 5mg/2ml solution for injection ampoules | £5.41 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Verapamil 80mg tablets | £2.51 | 84 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.1. Antianginal medicines · core
Angina pectoris
Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride) - 5.1.5.3. Medicines for cluster headache · core
Trigeminal autonomic cephalalgias
Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release) - 12.2. Antiarrhythmic medicines · core
Supraventricular tachyarrhythmia
Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride) | Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 28 Oct 2019 CALAN SR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions - US FDA 3 Oct 2019 VERELAN PM — safety-related labeling change
Labeling sections changed: Adverse Reactions; Drug Interactions - US FDA 1 Oct 2019 VERELAN — safety-related labeling change
Labeling sections changed: Drug Interactions - US FDA 20 Aug 2019 TARKA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions - US FDA 14 Sep 2017 CALAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions - US FDA 14 Sep 2017 COVERA-HS — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions - US FDA 18 Nov 2016 VERAPAMIL HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Drug Interactions - US FDA 24 Aug 2016 CALAN — safety-related labeling change
Labeling sections changed: Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.